基本信息
浏览量:1
职业迁徙
个人简介
His lab has a long-standing expertise in the development of antiviral strategies and drugs against emerging and neglected viral infections (such as dengue and other flaviviruses, Chikungunya, enteroviruses, noroviruses, coronaviruses, HEV and rabies). His lab is also intensively involved in the development of antivirals against SARS-CoV2. A second focus of the lab is the development of novel vaccine technologies. To that end the yellow fever vaccine is being used as a vector. Using this technology the team developed a potent single shot SARS-CoV2 vaccine candidate. The PLLAV (Plasmid Launched Live Attenuated Virus) technology, also developed in his lab, allows to rapidly engineer highly thermostable vaccines against multiple viral pathogens. Johan Neyts is past president of the International Society for Antiviral Research (www.isar-icar.com). Four classes of antivirals discovered in his laboratory have been licensed to major pharmaceutical companies (two on HCV, one on dengue and one on rhino/enteroviruses). He published >600 papers in peer reviewed journals and has given ~290 invited lectures; he is regularly interviewed by lay-press.
研究兴趣
论文共 476 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2024)
VIRUS EVOLUTIONno. 1 (2024): veae001-veae001
Delphine Diana Acar,Wojciech Witkowski,Magdalena Wejda, Ruifang Wei,Tim Desmet,Bert Schepens, Sieglinde De Cae,Koen Sedeyn,Hannah Eeckhaut,Daria Fijalkowska,Kenny Roose,Sandrine Vanmarcke,
EBIOMEDICINE (2024): 104960-104960
ACTA PHARMACEUTICA SINICA Bno. 1 (2024): 87-109
VIRUSES-BASELno. 1 (2024): 122
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPYno. 1 (2024): 172-178
Cell host & microbeno. 6 (2023): 856-860
引用0浏览0WOS引用
0
0
Scientific reportsno. 1 (2023): 3131-3131
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn